Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
4.
Cardiol Young ; 26(1): 209-13, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26194906

ABSTRACT

BACKGROUND: Those with cyanotic heart disease have an elevated bleeding risk but also are hypercoaguable. Treating haemodynamically significant thrombi in this unique cohort poses a monumental challenge. Case A 29-year-old women with tricuspid atresia and left pulmonary artery atresia presented with superior caval vein syndrome. She had a right modified Blalock-Taussig shunt as a neonate. A left modified Blalock-Taussig shunt performed later failed to establish flow to her left lung. At age 5, she had a Fontan procedure to the right lung but could not tolerate the physiology and had a low cardiac output syndrome. The Fontan was taken down and she was left with a Glenn anastamosis to the right pulmonary artery. She did well for years until she had dyspnea, upper extremity oedema and "facial fullness". On examination she was tachycardic, hypotensive, and more desaturated than baseline. She also had facial plethora. Decision-making Echocardiogram showed a large 9 × 3 mm nearly occlusive thrombus in the superior caval vein at the bifurcation of the left and right innominate veins. An emergent venogram confirmed the location and size of the thrombus. Given the thrombus burden and potential for distal embolisation through the Glenn to the single functional lung, we chose to treat the patient with thrombolytics. She had uncomplicated ICU course and was sent home on warfarin. Follow-up echocardiogram showed complete resolution of clot. CONCLUSION: This case shows the importance of history and physical exam in caring for this complex cohort of adult patients with CHD.


Subject(s)
Fibrinolytic Agents/therapeutic use , Postoperative Complications/drug therapy , Postoperative Complications/etiology , Superior Vena Cava Syndrome/drug therapy , Superior Vena Cava Syndrome/etiology , Tricuspid Atresia/complications , Adult , Female , Fontan Procedure , Humans
5.
Liver Transpl ; 20(2): 130-9, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24142390

ABSTRACT

The insertion of a transjugular intrahepatic portosystemic shunt (TIPS) is a minimally invasive procedure used to relieve the signs and symptoms of portal hypertension in patients with liver disease. The most common indications for placement are refractory ascites and variceal hemorrhage. In properly selected candidates, TIPS placement can serve as a bridge to liver transplantation. Expertise in TIPS placement after transplantation has significantly increased, which has allowed the procedure to become a viable option for retransplant candidates suffering the consequences of recurrent portal hypertension due to portal vein thrombosis, recurrent liver disease, or hepatic venous outflow obstruction (HVOO). However, TIPSs in liver transplant recipients are associated with a lower clinical response rate and a higher rate of complications in comparison with patients with native liver disease, and they are, therefore, generally reserved for patients with a Model for End-Stage Liver Disease (MELD) score ≤ 15 and ≤ 12 in patients with HCV. The role of TIPS placement in nonliver transplant recipients has been well studied in large trials, and it translates well into clinical applicability to candidates for orthotopic liver transplantation (OLT). However, the experience with OLT recipients is heterogeneous and restricted to small series. Thus, we focus here on reviewing the current literature and discussing the proper use of TIPSs in liver transplant recipients.


Subject(s)
Hemorrhage/surgery , Hypertension, Portal/surgery , Jugular Veins/surgery , Portal Vein/surgery , Portasystemic Shunt, Transjugular Intrahepatic/methods , Ascites/surgery , Budd-Chiari Syndrome/surgery , End Stage Liver Disease/surgery , Humans , Liver Diseases/surgery , Liver Transplantation , Reoperation , Severity of Illness Index , Venous Thrombosis/surgery
6.
Clin Gastroenterol Hepatol ; 9(9): 727-38, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21397731

ABSTRACT

Patients with cirrhosis are immunocompromised and susceptible to infections. Although detection and treatment of spontaneous bacterial peritonitis (SBP) have improved, overall survival rates have not increased greatly in recent decades-infection still increases mortality 4-fold among patients with cirrhosis. Hospitalized patients with cirrhosis have the highest risk of developing infections, especially patients with gastrointestinal (GI) hemorrhage. Bacterial infections occur in 32% to 34% of patients with cirrhosis who are admitted to the hospital and 45% of patients with GI hemorrhage. These rates are much higher than the overall rate of infection in hospitalized patients (5%-7%). The most common are SBP (25% of infections), urinary tract infection (20%), and pneumonia (15%). Bacterial overgrowth and translocation from the GI tract are important steps in the pathogenesis of SBP and bacteremia-these processes increase levels of endotoxins and cytokines that induce the inflammatory response and can lead to septic shock, multiorgan dysfunction, and death. A number of other bacterial and fungal pathogens are more common and virulent in patients with cirrhosis than in the overall population. We review the pathogenesis of infections in these patients, along with diagnostic and management strategies.


Subject(s)
Communicable Diseases/epidemiology , Communicable Diseases/immunology , Immune System Diseases/epidemiology , Immune System Diseases/etiology , Liver Cirrhosis/complications , Liver Cirrhosis/immunology , Communicable Diseases/mortality , Cross Infection/epidemiology , Cross Infection/immunology , Cross Infection/mortality , Humans , Immunocompromised Host
SELECTION OF CITATIONS
SEARCH DETAIL
...